Cubist Pharmaceuticals names chief executive

pharmafile | October 27, 2014 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing cubist, perez 

US biopharma firm Cubist Pharmaceuticals has named Robert Perez as its chief executive and who will begin the role from January next year.

Perez currently serves as the firm’s president and chief operating officer, and is to succeed Michael Bonney who is retiring from the leading role at the end of December. Bonney will become non-executive chair of Cubist’s board of directors. Current board chair, Kenneth Bate, will then become a lead independent director.

Perez has served in various senior positions at Cubist for 11 years. He was appointed COO in 2007, president in 2012 and has been a member of the board since April 2014. 

Kenneth Bate, chair of the board of directors at Cubist says: “We are delighted that Rob Perez will be Cubist’s next chief executive. Over the past decade, Rob has assumed roles of increasing seniority and has consistently demonstrated that he is ideally suited to lead Cubist during its next stage of growth.”  

“I am honoured by this appointment and the confidence Mike and the Board are placing in me,” adds Perez.”

Related Content

Merck logo

Merck launches new antibiotic in the UK

Merck has launched the first new drug in a class of antibiotics in the UK …


Cubist boosts antibiotics market presence

Cubist has followed-up its successful European approval for a new antibiotic by winning an endorsement …

Merck image

Merck acquires Swiss firm OncoEthix

Hot on the heals of its Cubist buyout Merck has confirmed the acquisition of OncoEthix, …

Latest content